Biopharmaceutical News and Research

RSS

Research describes novel molecules designed to treat or prevent COVID-19 infection

Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.

6 Nov 2020

Remdesivir metabolite GS-441524 inhibits SARS CoV-2 in mouse model, finds study

This new study titled, "Remdesivir Metabolite GS-441524 Efficiently Inhibits SARS-CoV-2 Infection in Mouse Model," was released online as a preprint on the bioRxiv* server, prior to undergoing the peer-review process.

2 Nov 2020

Thermo Fisher Scientific and Symphogen extend collaboration to boost drug discovery and development

Thermo Fisher Scientific, the world leader in serving science, and Symphogen, an affiliate of and the antibody center of excellence within the international pharmaceutical company, Servier, announce the extension of a strategic collaboration to deliver industry-proven, innovative characterization and quality control workflows for the simplified analysis of complex therapeutic proteins to advance biopharmaceutical discovery and development.

From Thermo Fisher Scientific Inc. 2 Nov 2020

McLean Hospital joins public-private partnership to find cure for schizophrenia

In September, McLean Hospital joined the National Institutes of Health, the U.S. Food and Drug Administration, and several public and private organizations to find early therapeutic interventions for people at risk for schizophrenia.

29 Oct 2020

Advancements in research on cancer signal transduction and treatment

Cancer is driven by numerous genetic and epigenetic changes occurring at the cellular level. These changes drive normal cells to proliferate and escape processes that usually regulate their survival and migration.

27 Oct 2020

Monoclonal Antibodies: Discovery, Characterization and Challenges

In this interview, News-Medical talks to David Apiyo, a senior manager of applications at Sartorius AG, about monoclonal antibody development and characterization.

22 Oct 2020

New inhaled treatment may lead to self-administered therapy for COVID-19

An inhaled treatment against the SARS-CoV-2 virus may lead to a future self-administered therapy for COVID-19, the pandemic that has killed more than 1 million people worldwide.

20 Oct 2020

COVID-19 vaccine candidate shows potent immune response

A COVID-19 vaccine candidate that underwent extensive preclinical testing at the University of Alabama at Birmingham this spring and summer shows potent preclinical immune responses - including several that distinguish it from other COVID-19 vaccine approaches - according to a preprint deposited in the BioRxiv repository this week.

13 Oct 2020

Nasal spray COVID-19 vaccine shows promising results in mice

With promising vaccines comes a new candidate that has shown potent pre-clinical immune responses. The vaccine, developed by scientists at the University of Alabama at Birmingham (UAB), induced a potent T-cell response at the mucus layer of the lungs, including killer CD8+ T-cells, which can recognize and kill virally infected cells.

12 Oct 2020

Genetic risk scoring of lipoprotein(a) can predict risk of atherosclerotic cardiovascular disease

Elevated levels of a little-known lipoprotein in the blood that may put people at high risk of cardiovascular disease can be as accurately detected by genetic testing as by conventional laboratory measurement, researchers at Massachusetts General Hospital (MGH) have found.

6 Oct 2020

Calibr's novel 'switchable' CAR-T cell therapy granted FDA's Fast Track designation

The U.S. Food and Drug Administration has granted Fast Track designation to a novel "switchable" CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the drug development and review process.

1 Oct 2020

Researchers identify a new method to produce miniaturized antibodies

Researchers at the University of Bath in the UK and biopharma company UCB have found a way to produce miniaturized antibodies, opening the way for a potential new class of treatments for diseases.

30 Sep 2020

Fourth Phase 3 clinical trial evaluating COVID-19 vaccine begins in the U.S.

A fourth Phase 3 clinical trial evaluating an investigational vaccine for coronavirus disease 2019 (COVID-19) has begun enrolling adult volunteers.

23 Sep 2020

Phase 2 clinical trial to examine the effects of razuprotafib on COVID-19 patients

Researchers at the University of Cincinnati and UC Health will host a Phase 2 clinical trial (NCT04511650) to examine the effects of a drug that targets blood vessel inflammation and injury in patients with COVID-19.

22 Sep 2020

Intra-CREATE grants awarded to support research on personalized medicine and cell therapy

Researchers from Critical Analytics for Manufacturing Personalized-Medicine, an interdisciplinary research group at Singapore-MIT Alliance for Research and Technology, MIT's research enterprise in Singapore, have been awarded Intra-CREATE grants from the National Research Foundation Singapore to help support research on retinal biometrics for glaucoma progression and neural cell implantation therapy for spinal cord injuries.

22 Sep 2020

Scientists investigate active plasma metabolite of remdesivir in SARS-CoV-2 mouse model

Using mouse models, scientists have investigated the active plasma metabolite of remdesivir, GS-441 524, and hydroxychloroquine as possible drug candidates in COVID-19. The research shows GS-441 524 could be an effective therapeutic drug against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while at the same time discounting hydroxychloroquine as a reliable anti-viral.

20 Sep 2020

ACC’s initiative can help cardiologists address critical patient needs, deliver high-quality care

The American College of Cardiology's ongoing COVID-19 response initiative is welcoming support from the Boehringer Ingelheim and Eli Lilly and Company Alliance to continue providing real-time clinical guidance on COVID-19.

18 Sep 2020

Oxford University and AstraZeneca resume COVID-19 vaccine trial

More than a hundred candidate vaccine trials against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19), are underway. About 35 are now undergoing clinical evaluation, and of these, nine are in the final phase of human trials, including the vaccine developed by Oxford University and the biopharmaceutical firm, AstraZeneca.

14 Sep 2020

Validation of AI tools for cancer immunotherapy may be a step closer

For Artificial Intelligence (AI) tools being developed at Case Western Reserve University to have impact in the fight against cancer, they're going to have to be validated in rigorous human clinical trials.

10 Sep 2020

Optibrium’s peer-reviewed study highlights the value of deep learning to impute drug discovery data

Optibrium, leading providers of software and services for drug discovery, today announced a peer-reviewed publication, ‘Practical Applications of Deep Learning to Impute Heterogeneous Drug Discovery Data’, in the Journal of Chemical Information and Modeling.